Amphastar Plans To Launch Second OTC Product Also In Emergency Medicine Category

 
• By Malcolm Spicer

Amphastar plans in 2024 to submit application to FDA to move its Rextovy 4mg naloxone hydrochloride intranasal formulation from Rx to OTC. Advertising to drive Primatene Mist awareness planned.

• Source: Shutterstock

More from Rx-to-OTC Switch

More from Health